Eli Lilly’s obesity pill helped lower weight, blood sugar in key Phase 3 trial

Taking stock of the drug industry, from the lab to the medicine chest

August 26, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Scott Olson/Getty Images STAT+ | Eli Lilly's obesity pill helped lower weight, blood sugar in key Phase 3 trial Lilly to file for regulatory approval for daily weight loss pill after GLP-1 drug orforglipron leads to 9.6% loss in body weight and lower blood sugar. By Elaine Chen STAT+ | New report details the state of the biotech industry in Mass. The results are grim Both public and private funding have plummeted as federal policy changes have thrown biotech into an era of uncertainty. By Marin Wolf — Boston Globe STAT+ | Akeso says its closely watched drug improved patient survival in a lung cancer trial Seen as a rival to Keytruda, the Chinese biotech's ivonescimab has quickly become one of the most closely watched drugs in oncology By Jonathan Wosen Adobe HHS terminates NIH program aimed at diversifying biomedical workforce Grant applications for the program, seen at odds with President Trump's ban on DEI efforts, had previously fallen out of favor. By Veronica Paulus

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser